Biomedical subjects

Jörn Wulf

Publications and source records attributed to Jörn Wulf.

9 recordsLinked to original sources

PubMed2006

3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey.

The effects of two modalities of dose-escalated radiotherapy on health-related quality of life (HRQOL) were compared. Forty-one consecutive patients were treated with a 3-D conformal (3-DC) boost to 74 Gy, and 43 with high-dose rate (HDR) brachytherapy boost (2x9 Gy), following 3-D conformal treatment to 46 Gy. Median age was 70 years in both groups, median initial PSA was 7.9 microg/l in 3-DC boost patients and 8.1 microg/l in HDR boost patients. Stage was or=7 in 52% and 47%, respectively. HRQOL was assessed cross-sectionally using EORTC QLQ-C30 and organ-specific PR25 modules 3--32 (median 19) and 4--25 (median 14) months after treatment, respectively. Questionnaires were completed by 93% and 97% of patients, respectively. Diarrhea and insomnia scores were significantly increased in both groups. In the PR25 module, scores of 3-DC boost and HDR boost patients for urinary, bowel and treatment-related symptoms were similar. Among responders, 34% of 3-DC boost patients and 86% of HDR boost patients had severe erectile problems. Dose escalation in prostate cancer by either 3-DC boost to 74 Gy or HDR brachytherapy boost appears to result in similar HRQOL profiles.

Brachytherapy↗

PubMed2005

Target motion measurement without implanted markers and its validation by comparison with manually obtained data.

For an effective radiotherapy the exact tumor location must be determined. The localization has to take into account patient's setup position as well as internal organ motion. Among the different localization methods, the use of a computer tomography (CT) scanner in the therapy room has been proposed recently. Achieving a CT with the patient on the therapy couch, a patient's treatment position is captured. We present a method to locate tumor considering internal organ motion and displacements due to respiration. We tested the method with prostate and lung patients. The method found the most probable tumor position as well as, for high-mobility tumors located in the lung, its trajectory during the respiratory cycle. The results of this novel method were validated by comparison with manually determined target position.

Female↗

PubMed2004

Outcome of postoperative treatment for rectal cancer UICC stage II and III in day-to-day clinical practice. Results from a retrospective quality control analysis in six institutions in North Bavaria (Germany).

BACKGROUND AND PURPOSE: Radiochemotherapy (RChT) as adjuvant treatment for rectal cancer UICC stage II/III has been recommended by the National Cancer Institute (NCI) since 1991 and in Germany since 1994. Quality and results of postoperative treatment in day-to-day clinical practice in a complete region are evaluated retrospectively in a multi-institutional approach. PATIENTS AND METHODS: 534 patients from six institutions treated between 1993 and 1998 were evaluated. The institutions covered a complete region with radiotherapeutic care. Patients were staged as follows: UICC I 1%, II 28%, III 69%, and IV 2%. 92% received RChT, 8% radiotherapy (RT) alone. Median follow-up of patients was 47 months (17-91 months). RESULTS: Only about 37% of expected patients were referred for postoperative treatment. The 5-year actuarial rate was as follows: local control 75% (63-84%), freedom from distant metastases 56% (44-63%), disease-free survival (DFS) 53% (42-59%), and overall survival (OS) 53% (45-64%). In multivariate analysis, local control was significantly influenced by T- and N-category, tumor grading, and RChT instead of RT alone. 6% (2-11%) of patients showed involved resection margins, in 33% of patients categorized pN0 less than the required twelve lymph nodes were examined, both leading to a significant decrease of local control. CONCLUSION: While the quality of adjuvant treatment followed consensus guidelines, the number of referred patients which was lower as expected and the inferior treatment results as compared to randomized studies indicate that the consensus recommendations for adjuvant treatment have not been fully accepted. Instead of patient referral according to UICC stage, patient selection by the surgeons has been performed according to individual risk factors. Efforts have to be made not only to improve treatment results in randomized studies but also to transfer and control these standards in daily practice.

Actuarial Analysis↗

PubMed2004

Positional variability of a tandem applicator system in HDR brachytherapy for primary treatment of cervix cancer. Analysis of the anatomic pelvic position and comparison of the applicator positions during five insertions.

PURPOSE: Evaluation of the inter- and intraindividual applicator variability of multiple high-dose-rate (HDR) brachytherapy applications for primary treatment of cancer of the uterine cervix. MATERIAL AND METHODS: Retrospective analysis of 460 pairs of orthogonal X-ray films for conventional treatment in 92 patients with five intrauterine applications using an HDR tandem applicator. Measurement of the position of the applicator origin relative to a bony reference system in three dimensions. Evaluation of the differences of the applicator position in all 460 applications (interindividual variability), of the five applications in a single patient (intraindividual variability) and of the intraindividual variability relative to the applicator position at the first application. RESULTS: The position of the applicator origin in the pelvis ranged from 23 mm cranial and 55 mm caudal to the top of femoral heads, 23 mm right and 27 mm left to the pelvic midline, and 6-53 mm dorsal to the mid of the femoral heads. Standard deviation (SD) of interindividual applicator variability was 12.9 mm (minimum/maximum -55/+23 mm, mean -13.6 mm) in longitudinal, 5.1 mm (-27/+23 mm, mean 1.6 mm) in lateral, and 7.6 mm (6/53 mm, mean 26 mm) in anterior-posterior [AP] direction. SD of intraindividual variability was 5.5 mm (-21/+23 mm, mean 0 mm) in longitudinal, 2.5 mm (-17/+19 mm, mean 0 mm) in lateral, and 4.2 mm (-15/+18 mm, mean 0 mm) in AP direction compared to intraindividual variability relative to the first insertion with an SD of 8.9 mm (-23/+36 mm, mean 2.8 mm) in longitudinal, 4.0 mm (-11/+23 mm, mean 0 mm) in lateral, and 6.8 mm (-27/+17 mm, mean -0.8 mm) in AP direction. CONCLUSION: Intraindividual applicator variability is significantly smaller than interindividual variability. Applicator-related procedures such as midline shielding or dose matching of tele- and brachytherapy should be performed with information on at least one individual applicator position.

Adenocarcinoma↗

PubMed2004

How can we further improve radiotherapy for stage-III non-small-cell lung cancer?

Combined modality treatment in advanced NSCLC has produced some gain in treatment outcome. Local control as addressed by radiotherapy is still a significant site of failure. Doses higher than achieved by conventional conformal radiotherapy are shown to result in better control rates. Volume restriction seems to be the most important issue in dose escalation. Integration of PET imaging into target definition, omission of clinically uninvolved lymph-node areas and measures to decrease set-up and movement uncertainties are explored. Introduction of risk estimation based on dose-volume analysis for dose prescription may further optimise individual treatment.

Algorithms↗

PubMed2004

Stereotactic boost irradiation for targets in the abdomen and pelvis.

Based on the experience of stereotactic irradiation of lung and liver tumors the feasibility of stereotactic boost irradiation to abdominal and pelvic tumors was evaluated. Twenty-one patients with inoperable tumors received a stereotactic boost of 2-3 x 5Gy/PTV-enclosing-100% isodose with normalization to 150% at the isocenter after normofractionated irradiation of 45-50.4Gy. Actuarial local control (16/21 targets) was 96/70% after 12 and 24 months. Treatment was feasible and well tolerated.

Abdominal Neoplasms↗

PubMed2004

A table top suited for CT and radiotherapy.

A radiotherapy table top was to be designed and manufactured, suitable for computer tomography in the same room. The aim was a distortion of the dose distribution by the table top of not more than 4% in small subunits of the target volume (TV) and less than 2% for the mean dose in the TV. Only negligible artifacts in the CT slices should occur in order to assure the exact relocalization of the TV. The table top manufactured of carbon fiber reinforced plastic was constructed by means of finite-element-algorithms. The trapezoidal shaped sandwich plate is supported with tapered beams. The small side of the table can penetrate a 60 cm CT-gantry. When turned, the table top allows large ap-pa opposed fields without irradiating through the beams. Transmission measurements were performed with an ionization chamber under different irradiation angles to determine the influence of the beams and the covering plate. Additionally, a portal imaging device (PID) was used for comparison. It was found that the deflection and torsion of the carbon fiber table top was smaller than for the original. The transmission of the sandwich plate was 97.5% (18 MV) and 96.5% (6 MV photons) respectively. If the irradiation of the beam walls can not be avoided the transmission is not in a critical range. The CT-slices show only minor artifacts along the side walls of the beams. The localization of the tumor or the TV is not restricted.

Artifacts↗

PubMed2003

Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver.

BACKGROUND AND PURPOSE: Previous analyses of target reproducibility in extracranial stereotactic radiotherapy have revealed standard security margins for planning target volume (PTV) definition of 5mm in axial and 5-10mm in longitudinal direction. In this study the reproducibility of the clinical target volume (CTV) of lung and liver tumors within the PTV over the complete course of hypofractionated treatment is evaluated. The impact of target mobility on dose to the CTV is assessed by dose-volume histograms (DVH). MATERIALS AND METHODS: Twenty-two pulmonary and 21 hepatic targets were treated with three stereotactic fractions of 10 Gy to the PTV-enclosing 100%-isodose with normalization to 150% at the isocenter. A conformal dose distribution was related to the PTV, which was defined by margins of 5-10mm added to the CTV. Prior to each fraction a computed tomography (CT)-simulation over the complete target volume was performed resulting in a total of 60 CT-simulations for lung and 58 CT-simulations for hepatic targets. The CTV from each CT-simulation was segmented and matched with the CT-study used for treatment planning. A DVH of the simulated CTV was calculated for each fraction. The target coverage (TC) of dose to the simulated CTV was defined as the proportion of the CTV receiving at least the reference dose (100%). RESULTS: A decrease of TC to <95% was found in 3/60 simulations (5%) of pulmonary and 7/58 simulations (12%) of hepatic targets. In two of 22 pulmonary targets (9%) and in four of 21 hepatic targets (19%) a TC of <95% occurred in at least one fraction. At risk for a decreased TC <95% were pulmonary targets with increased breathing mobility and hepatic targets with a CTV exceeding 100 cm(3). CONCLUSIONS: Target reproducibility was precise within the reference isodose in 91% of lung and 81% of liver tumors with a TC of the complete CTV >or=95% at each fraction of treatment. Pulmonary targets with increased breathing mobility and liver tumors >100 cm(3) are at risk for target deviation exceeding the standard security margins for PTV-definition at least for one fraction and require individual evaluation of sufficient margins.

Adolescent↗

PubMed2002

Extracranial stereotactic radiotherapy: evaluation of PTV coverage and dose conformity.

During the past few years the concept of cranial stereotactic radiotherapy has been successfully extended to extracranial tumoral targets. In our department, hypofractionated treatment of tumours in lung, liver, abdomen, and pelvis is performed in the Stereotactic Body Frame (ELEKTA Instrument AB) since 1997. We present the evaluation of 63 consecutively treated targets (22 lung, 21 liver, 20 abdomen/pelvis) in 58 patients with respect to dose coverage of the planning target volume (PTV) as well as conformity of the dose distribution. The mean PTV coverage was found to be 96.3% +/- 2.3% (lung), 95.0% +/- 4.5% (liver), and 92.1% +/- 5.2% (abdomen/pelvis). For the so-called conformation number we obtained values of 0.73 +/- 0.09 (lung), 0.77 +/- 0.10 (liver), and 0.70 +/- 0.08 (abdomen/pelvis). The results show that highly conformal treatment techniques can be applied also in extracranial stereotactic radiotherapy. This is primarily due to the relatively simple geometrical shape of most of the targets. Especially lung and liver targets turned out to be approximately spherically/cylindrically shaped, so that the dose distribution can be easily tailored by rotational fields.

Abdominal Neoplasms↗